AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

IMMUTEP LTD

0.290

+0.0103.57%

Volume:1.10M

Turnover:317.41K

Market Cap:422.12M

PE:-8.82

High:0.295

Open:0.280

Low:0.280

Close:0.280

Loading ...

Overview Company News Filings

Positive Data From Phase Ii Trial in Soft Tissue Sarcoma Presented at Ctos 2024 Annual Meeting

THOMSON REUTERS

Positive Data from Phase II Trial in Soft Tissue Sarcoma Presented at CTOS 2024 Annual Meeting

Immutep Reports Positive Data from Soft Tissue Sarcoma Trial; Shares Up 5%

MT Newswires Live

Immutep’s efti combination therapies show strong efficacy in soft tissue sarcoma and lung cancer trials

Immutep Reports Positive Survival Data from Non-Small Cell Lung Cancer Study; Shares Up 8%

MT Newswires Live

3 ASX healthcare shares going gangbusters on Thursday

The 7 zombie companies lurking on the ASX 300

Immutep Limited's (ASX:IMM) institutional shareholders had a great week as one-year returns increased after a 11% gain last week

Simply Wall St.

Immutep (ASX:IMM) shareholders have endured a 51% loss from investing in the stock three years ago

Simply Wall St.

Immutep Ltd: Expected Cash Reach to End of Cy2026

THOMSON REUTERS

Immutep Quarterly Activities Report Q1 FY25

Immutep to Present New Phase IIb Data in PD-L1 Negative (CPS <1) Head and Neck Cancer at ESMO Immuno-Oncology 2024

BRIEF-Immutep Announces First-In-Human Phase I Study Of IMP761 Progresses To Dose Escalation Portion Of Trial

Immutep Announces First-in-Human Phase I Study of Imp761 Progresses to Dose Escalation Portion of Trial

THOMSON REUTERS

Immutep Ltd - Trial Progresses to Part B Dose Escalation Phase

THOMSON REUTERS

Immutep Ltd - First Safety Data Anticipated Before Year End

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/IMM.AU/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IMM.AU"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IMM.AU\",,,,,undefined,":{"symbol":"IMM.AU","market":"AU","secType":"STK","nameCN":"IMMUTEP LTD","latestPrice":0.29,"timestamp":1741583520000,"preClose":0.28,"halted":0,"volume":1100242,"delay":0,"changeRate":0.035714,"change":0.01,"floatShares":1251930614,"shares":1455589575,"eps":-0.032898,"lyrEps":-0.035565,"pbRate":2.45,"amount":317406,"amplitude":0.053571,"volumeRatio":0.17495813934303367,"dividePrice":0,"prevYearClose":0.365,"fiveDayClose":0.305,"twentyDayClose":0.32},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IMM.AU\",,,,,undefined,":{"symbol":"IMM.AU","floatShares":1251930614,"roa":"-20.35%","roe":"-30.45%","lyrEps":-0.035565,"volumeRatio":0.17495813934303367,"shares":1455589575,"dividePrice":0,"high":0.295,"amplitude":0.053571,"preClose":0.28,"low":0.28,"week52Low":0.23,"pbRate":"2.45","psRate":"86.52","week52High":0.46,"institutionHeld":0,"latestPrice":0.29,"eps":-0.032898,"divideRate":0,"volume":1100242,"delay":0,"ttmEps":-0.032898,"open":0.28,"prevYearClose":0.365,"prevWeekClose":0.28,"prevMonthClose":0.31,"prevQuarterClose":0.365,"fiveDayClose":0.305,"twentyDayClose":0.32,"sixtyDayClose":0.34},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMM.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2024-06-05","symbol":"IMM.AU","defaultRemindTime":1717545600000,"type":"split","dateTimestamp":1717509600000,"forFactor":948148,"toFactor":1000000,"ratio":0.9481480000000001}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMM.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IMM.AU\",pageSize:16,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2483877831","title":"Positive Data From Phase Ii Trial in Soft Tissue Sarcoma Presented at Ctos 2024 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2483877831","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483877831?lang=en_us&edition=fundamental","pubTime":"2024-11-14 21:00","pubTimestamp":1731589201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nTUAB6Q7C1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMM.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2483787758","title":"Positive Data from Phase II Trial in Soft Tissue Sarcoma Presented at CTOS 2024 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2483787758","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483787758?lang=en_us&edition=fundamental","pubTime":"2024-11-14 21:00","pubTimestamp":1731589200,"startTime":"0","endTime":"0","summary":"Efti in combination with pembrolizumab and radiotherapy demonstrates significant efficacy in the neoadjuvant setting in patients with soft tissue sarcoma. Over three-fold increase in tumour hyalinization, the primary endpoint of the study and an important predictor of overall survival, as compared to historical results from radiotherapy alone. SYDNEY, AUSTRALIA, Nov. 14, 2024  -- Immutep Limited  , a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces the presentation of new data from EFTISARC-NEO, a Phase II investigator-initiated trial of eftilagimod alpha  in combination with radiotherapy plus KEYTRUDA  for patients with soft tissue sarcoma , at the Connective Tissue Oncology Society  2024 Annual Meeting. Based on preliminary analysis among 21 patients available for primary endpoint assessment, the triple combination therapy demonstrates significant efficacy in the neoadjuvant setting for resectable STS.Dr. F","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/rMGJzQlu_.sxjdfFCHAlRg--~B/aD0xMDM7dz0yNDY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/caf92fc65a13b56708c85c7546e3ac3d","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/rMGJzQlu_.sxjdfFCHAlRg--~B/aD0xMDM7dz0yNDY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/caf92fc65a13b56708c85c7546e3ac3d"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/positive-data-phase-ii-trial-130000666.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["IMM.AU","CTOS","IMMP","BK7067","BK4104","BK7508","BK4139"],"gpt_icon":1},{"id":"2483292896","title":"Immutep Reports Positive Data from Soft Tissue Sarcoma Trial; Shares Up 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483292896","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483292896?lang=en_us&edition=fundamental","pubTime":"2024-11-14 11:09","pubTimestamp":1731553761,"startTime":"0","endTime":"0","summary":"Biotechnology company Immutep  said its EFTISARC-NEO, a second phase trial of eftilagimod alpha in combination with radiotherapy and KEYTRUDA for patients with soft tissue sarcoma, showed positive data, according to a Thursday filing with the Australian bourse.The triple combination therapy, based on a preliminary analysis of 21 patients, showed \"significant\" efficacy in the neoadjuvant setting for resectable soft tissue sarcoma, the filing said.The study also found an over three-fold increase in tumor hyalinization, a crucial predictor of overall survival, compared with historical results from radiotherapy alone.The EFTISARC-NEO study, led by the Maria Skodowska-Curie National Research Institute of Oncology, is expected to enroll 40 patients in the first quarter of 2025, according to the filing.The new data from the study was presented at the Connective Tissue Oncology Society annual meeting, the filing added.Immutep shares rose nearly 5% in afternoon trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMM.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2483989520","title":"Immutep’s efti combination therapies show strong efficacy in soft tissue sarcoma and lung cancer trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2483989520","media":"Small Caps","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483989520?lang=en_us&edition=fundamental","pubTime":"2024-11-14 10:39","pubTimestamp":1731551943,"startTime":"0","endTime":"0","summary":"Immutep  has presented new data from a Phase II investigator-initiated trial of eftilagimod alpha  in combination with radiotherapy plus Keytruda  for patients with soft tissue sarcoma .Based on preliminary analysis of 21 patients available for primary endpoint assessment, the trial at Maria Skodowska-Curie National Research Institute of Oncology  in Poland showed that the triple-combination therapy demonstrated significant efficacy in the neoadjuvant setting for resectable STS.The combination was reported to be safe, with no serious toxicities related to efti or pembrolizumab.“We are pleased with the strength of these preliminary results in this difficult-to-treat cancer,” Immutep chief scientific officer Dr Frédéric Triebel said.“To see 71.4% of soft tissue sarcoma patients achieving a positive pathologic response is very promising, especially as strong efficacy has been observed across different STS subtypes.”Immutep has also announced positive data from an Insight-003 Phase I trial","market":"us","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2024/11/Immutep-ASX-IMM-eftilagimod-alpha-STS-trial-success.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2024/11/Immutep-ASX-IMM-eftilagimod-alpha-STS-trial-success.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://smallcaps.com.au/immutep-efti-therapies-strong-efficacy-soft-tissue-sarcoma-lung-cancer-trials/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["BK7067","BK7508","IMM.AU"],"gpt_icon":0},{"id":"2483893286","title":"Immutep Reports Positive Survival Data from Non-Small Cell Lung Cancer Study; Shares Up 8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483893286","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483893286?lang=en_us&edition=fundamental","pubTime":"2024-11-14 10:20","pubTimestamp":1731550831,"startTime":"0","endTime":"0","summary":"Biotechnology company Immutep  obtained positive survival data from the Insight-003 first phase trial, evaluating eftilagimod alpha in combination with Keytruda and chemotherapy for the first-line treatment of metastatic non-squamous non-small cell lung cancer, according to a Thursday filing with the Australian bourse.The study results, with a minimum follow-up of 22 months, showed a median overall survival of 32.9 months, a median progression-free survival of 12.7 months, and a 24-month overall survival rate of 81%, the filing said.Results also show no new safety signals.Insight-003, led by the Frankfurt Institute of Clinical Cancer Research, is nearing patient enrollment completion, with further data from the trial expected in 2025, according to the filing.Immutep shares rose past 8% in midday trade Thursday.Price : $0.34, Change: $+0.03, Percent Change: +8.06%","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7508","BK4125","LU0994945656.USD","AUD","IMM.AU","LU0426417589.USD","LU2238339852.HKD","LU1043141123.HKD","LU0345774631.USD","LU0426412945.USD"],"gpt_icon":0},{"id":"2483860830","title":"3 ASX healthcare shares going gangbusters on Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=2483860830","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483860830?lang=en_us&edition=fundamental","pubTime":"2024-11-14 09:00","pubTimestamp":1731546012,"startTime":"0","endTime":"0","summary":"Three ASX healthcare shares are making their shareholders very happy today, posting gains of 5%, 12% and 19% respectively in morning trade. And this strong performance comes despite some broader healthcare sector headwinds on Thursday, which sees the S&P/ASX 200 Health Care Index  down 0.4% at this same time. So, which three ASX healthcare shares are bucking the trend and flying higher?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/11/14/3-asx-healthcare-shares-going-gangbusters-on-thursday/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7096","BK7501","NEU.AU","BK7508","MSB.AU","BK7067","IMM.AU"],"gpt_icon":1},{"id":"2483055804","title":"The 7 zombie companies lurking on the ASX 300","url":"https://stock-news.laohu8.com/highlight/detail?id=2483055804","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483055804?lang=en_us&edition=fundamental","pubTime":"2024-11-13 04:00","pubTimestamp":1731441610,"startTime":"0","endTime":"0","summary":"The media has been circling WiseTech Global's Richard White and Mineral Resources' Chris Ellison in recent months. White has stepped down while Ellison plans to step down from his post within 18 months. Both were the result of investigations and intense scrutiny.Although there are red flags surrounding both these companies, Plato Investment Management's Dr David Allensuggests these are not the only companies in the ASX 300 that investors should be taking notes on.Zombie companies are defined as businesses where their interest costs or debt repayments exceed their cash flows over long periods of time, say three years or more. Usually, they trade at high multiples and have a captivating story that sees investors take a punt on these profitless or hardly revenue-generating companies - like a junior mining business sitting on a very large pot of gold, or a biotech with plans to revolutionise healthcare.\"If a company's got negative operating cash flow and it can't even cover its interest co","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/the-7-zombie-companies-lurking-on-the-asx-300","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/the-7-zombie-companies-lurking-on-the-asx-300","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["BK7508","INR.AU","NVX.AU","BK7503","ADT.AU","BOE.AU","BK7083","XKO.AU","BK7095","MSB.AU","BK7067","XJO.AU","CAD.AU","BK7504","BK7084","MIN.AU","BK7507","BK7016","WTC.AU","IMM.AU","XAO.AU","NXG.AU","BK7501"],"gpt_icon":0},{"id":"2482471620","title":"Immutep Limited's (ASX:IMM) institutional shareholders had a great week as one-year returns increased after a 11% gain last week","url":"https://stock-news.laohu8.com/highlight/detail?id=2482471620","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482471620?lang=en_us&edition=fundamental","pubTime":"2024-11-12 05:35","pubTimestamp":1731360942,"startTime":"0","endTime":"0","summary":"Key Insights Institutions' substantial holdings in Immutep implies that they have significant influence over the...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-imm/immutep-shares/news/immutep-limiteds-asximm-institutional-shareholders-had-a-gre","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IMM.AU","IMMP","BK7067","BK7508","BK4139"],"gpt_icon":0},{"id":"2481959188","title":"Immutep (ASX:IMM) shareholders have endured a 51% loss from investing in the stock three years ago","url":"https://stock-news.laohu8.com/highlight/detail?id=2481959188","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481959188?lang=en_us&edition=fundamental","pubTime":"2024-11-07 04:34","pubTimestamp":1730925253,"startTime":"0","endTime":"0","summary":"If you love investing in stocks you're bound to buy some losers. But long term Immutep Limited  shareholders have had a particularly rough ride in the last three year. Sadly for them, the share price is down 52% in that time.Now let's have a look at the company's fundamentals, and see if the long term shareholder return has matched the performance of the underlying business.While the broader market gained around 21% in the last year, Immutep shareholders lost 2.4%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. On the bright side, long term shareholders have made money, with a gain of 1.2% per year over half a decade. It could be that the recent sell-off is an opportunity, so it may be worth checking the fundamental data for signs of a long term growth trend. It's always interesting to track share price performance over the longer term. But to understand Immutep better, we need to consider many other factors. For insta","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immutep-asx-imm-shareholders-endured-203413664.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IMMP","IMM.AU","BK4139"],"gpt_icon":0},{"id":"2479409914","title":"Immutep Ltd: Expected Cash Reach to End of Cy2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2479409914","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479409914?lang=en_us&edition=fundamental","pubTime":"2024-10-29 20:18","pubTimestamp":1730204301,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241029:nFWN3M51BC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMM.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2479406502","title":"Immutep Quarterly Activities Report Q1 FY25","url":"https://stock-news.laohu8.com/highlight/detail?id=2479406502","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479406502?lang=en_us&edition=fundamental","pubTime":"2024-10-29 20:00","pubTimestamp":1730203200,"startTime":"0","endTime":"0","summary":"Positive feedback received from US FDA regarding the planned TACTI-004 Phase III in first-line non-small cell lung cancer successfully concluding regulatory preparations for the trial design. Efti in combination with MSD’s KEYTRUDA reports positive efficacy and favourable safety in first-line head and neck cancer in TACTI-003 Phase IIb trial. First participant successfully dosed in the first-in-human Phase I trial of IMP761, a novel LAG-3 agonist antibody designed to treat autoimmune diseases. Immutep added to the S&P ASX300 Index, recognising its considerable growth and enhancing market visibility. Immutep has a strong aggregate cash, cash equivalent and term deposit position of A$172.3 million as at 30 September 2024 with an expected cash reach to the end of CY2026.In July, Immutep reported updated positive efficacy and safety results from Cohort B of the TACTI-003 Phase IIb trial at an ESMO Virtual Plenary session. In patients with negative PD-L1 expression  in Cohort B, efti in com","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/rMGJzQlu_.sxjdfFCHAlRg--~B/aD0xMDM7dz0yNDY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/caf92fc65a13b56708c85c7546e3ac3d","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/rMGJzQlu_.sxjdfFCHAlRg--~B/aD0xMDM7dz0yNDY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/caf92fc65a13b56708c85c7546e3ac3d"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immutep-quarterly-activities-report-q1-120000760.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0208291251.USD","IE00B1BXHZ80.USD","LU1057294990.SGD","LU0965509101.SGD","LU0985320562.USD","IMMP","BK4516","LU1116320737.USD","BK4104","BK4534","LU1941712264.USD","MRK","LU0320765489.SGD","BK4007","IE00BJT1NW94.SGD","BK4588","LU0861579265.USD","BK4139","LU0965509010.AUD","IE000M9KFDE8.USD","LU1934455194.USD","IE00BLSP4239.USD","LU0965509283.SGD","IMM.AU","CTOS","BK4559","LU0203345920.USD","LU1066051225.USD","LU1093756325.SGD","LU0106261372.USD","LU1066053197.SGD","LU1066051811.HKD","LU1917777945.USD","IE0002141913.USD","LU0965508806.USD","LU1585245621.USD","LU0238689110.USD","IE00BFTCPJ56.SGD","INAQU","IE00B4R5TH58.HKD","LU0289739699.SGD","LU1093756168.USD","IE00BLSP4452.SGD","LU1061106388.HKD","LU0266013472.USD","LU1934455277.USD","LU0006306889.USD","LU0203347892.USD","LU1934455863.HKD","LU1066051498.USD"],"gpt_icon":1},{"id":"2478104957","title":"Immutep to Present New Phase IIb Data in PD-L1 Negative (CPS <1) Head and Neck Cancer at ESMO Immuno-Oncology 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2478104957","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478104957?lang=en_us&edition=fundamental","pubTime":"2024-10-28 20:00","pubTimestamp":1730116800,"startTime":"0","endTime":"0","summary":"TACTI-003 Cohort B: Eftilagimod Alpha  and Pembrolizumab in First-Line Recurrent or Metastatic Head & Neck Squamous Cell Carcinoma with CPS <1. Martin Forster, M.D., Ph.D., University College London  Cancer Institute and UCL Hospital NHS Foundation, London, UK. Abstracts will be made available on the ESMO I-O website on 5 December 2024 at 00:05 CET. The poster containing new data, not in the abstract, will be available on the Posters & Publications section of Immutep’s website after its presentation on 12 December 2024.About Immutep Immutep is a clinical-stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 , and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to m","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/rMGJzQlu_.sxjdfFCHAlRg--~B/aD0xMDM7dz0yNDY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/caf92fc65a13b56708c85c7546e3ac3d","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/rMGJzQlu_.sxjdfFCHAlRg--~B/aD0xMDM7dz0yNDY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/caf92fc65a13b56708c85c7546e3ac3d"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immutep-present-phase-iib-data-120000780.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1169590202.USD","UCL","LU1169589451.USD","BK4124","PD","IMMP","BK4132","CPS","BK4139","IMM.AU","BK4023"],"gpt_icon":1},{"id":"2476128571","title":"BRIEF-Immutep Announces First-In-Human Phase I Study Of IMP761 Progresses To Dose Escalation Portion Of Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2476128571","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476128571?lang=en_us&edition=fundamental","pubTime":"2024-10-17 20:15","pubTimestamp":1729167356,"startTime":"0","endTime":"0","summary":"Oct 17  - Immutep Ltd   :   * IMMUTEP ANNOUNCES FIRST-IN-HUMAN PHASE I STUDY OF IMP761 PROGRESSES TO DOSE ESCALATION PORTION OF TRIAL   * IMMUTEP LTD - TRIAL PROGRESSES TO PART B DOSE ESCALATION PHASE   * IMMUTEP LTD - FIRST SAFETY DATA ANTICIPATED BEFORE YEAR ENDSource text for Eikon:    Further company coverage:    ","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","IMM.AU"],"gpt_icon":0},{"id":"2476147998","title":"Immutep Announces First-in-Human Phase I Study of Imp761 Progresses to Dose Escalation Portion of Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2476147998","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476147998?lang=en_us&edition=fundamental","pubTime":"2024-10-17 20:00","pubTimestamp":1729166401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241017:nTUA4TFJXW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMM.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2476147153","title":"Immutep Ltd - Trial Progresses to Part B Dose Escalation Phase","url":"https://stock-news.laohu8.com/highlight/detail?id=2476147153","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476147153?lang=en_us&edition=fundamental","pubTime":"2024-10-17 20:00","pubTimestamp":1729166401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241017:nTUA4TFJXW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMM.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2476147119","title":"Immutep Ltd - First Safety Data Anticipated Before Year End","url":"https://stock-news.laohu8.com/highlight/detail?id=2476147119","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476147119?lang=en_us&edition=fundamental","pubTime":"2024-10-17 20:00","pubTimestamp":1729166401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241017:nTUA4TFJXW:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","IMM.AU","BK7508"],"gpt_icon":0}],"pageSize":16,"totalPage":4,"pageCount":3,"totalSize":63}]}}